On Wednesday, Curis, Inc. (NASDAQ:CRIS)’s shares gained 7.22%, and closed at $2.82, after a biotechnology corporation, declared that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead proprietary drug candidate, CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is presently under investigation in Phase 1 clinical studies in patients with relapsed or refractory lymphomas or multiple myeloma in addition to in patients with advanced/ relapsed solid tumors, counting hormone receptor positive (HR+)/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements.
Curis, Inc., a biotechnology corporation, engages in the discovery and development of drug candidates for the treatment of human cancers. The corporation develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)’s shares jumped 7.05%, and settled at $9.72, during the last trading session on Wednesday, after a clinical stage biopharmaceutical corporation, declared that the corporation has been selected to receive a grant from the Defense Advanced Research Projects Agency (DARPA) to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola. Inovio is the prime contractor on the DARPA program. Other collaborators are: MedImmune, the global biologics research and development arm of AstraZeneca; GeneOne Life Sciences (011000.KS) and its manufacturing partner, VGXI, Inc.; and Professor David B. Weiner, PhD, professor of Pathology and Laboratory Medicine at The Perelman School of Medicine at the University of Pennsylvania, Emory University and Vanderbilt University.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical corporation, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
At the end of Wednesday’s trade, E-House (China) Holdings Limited (NYSE:EJ)’s shares climbed 9.87%, and closed at $6.12, after a leading real estate services corporation in China, recently declared that it has reached a definitive contract with Jupai Holdings Limited, a leading third-party wealth administration service provider in China, regarding the projected transfer of E-House Capital, the asset administration business unit of E-House focusing on the design and administration of real estate or related investment projects and funds, to Jupai. E-House, through E-House (China) Capital Investment Administration Limited, a wholly owned partner of E-House, presently owns about 33% of the total issued and outstanding shares of Jupai.
E-House also declared that Jupai has presented, on a confidential basis, a draft registration statement on Form F-1 in compliance with the U.S. Securities Act of 1933, as amended to the U.S. Securities and Exchange Commission for the Projected IPO. The Projected IPO is predictable to commence as capital markets conditions permit and is subject to Jupai’s public filing of the registration statement with the SEC in compliance with the Securities Act, and the SEC declaring such registration statement effective. The projected number of American depositary shares to be offered and sold in the Projected IPO has not yet been determined.
E-House (China) Holdings Limited, through its auxiliaries, operates as a real estate services corporation primarily in the People’s Republic of China. It operates through Real Estate Online Services, Real Estate Brokerage Services, Real Estate Information and Consulting Services, and Other Services segments.
Global Payments Inc. (NYSE:GPN), ended its Wednesday’s trading session with 6.92% gain, and closed at $98.61, hitting new 52-week high of $99.95, after Global Payments, declared results for its fiscal third quarter ended February 28, 2015.
- Proceeds grew 8% to $666.9 million, contrast to $616.5 million in the third quarter of fiscal 2014.
- Cash diluted earnings per share grew 19% to $1.14, contrast to $0.96 in the third quarter of fiscal 2014.
- GAAP diluted earnings per share were $0.93, contrast to $0.76 in the third quarter of fiscal 2014.
Global Payments Inc. provides electronic payments transaction processing services. The corporation operates in two segments, North America Merchant Services and International Merchant Services. It offers processing solutions for credit cards, debit cards, electronic payments, and check-related services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
